Reproductive health and endocrine disruption in women with breast cancer: a pilot study

Ashlesha Patel, Alicia Roston, Almae Uy, Erika Radeke, Arden Roston, Louis Keith, Howard A. Zaren

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Conclusions: The assessment and algorithm were useful in managing patients’ reproductive health needs. Chemotherapy-induced endocrine disruption impacted reproductive health.

Methods: This prospective observational pilot study was set in an urban, public hospital. Newly diagnosed premenopausal breast cancer patients between 18 and 49 years old were recruited for this study prior to chemotherapy initiation. As the intervention, these patients received a reproductive health assessment and care per the study algorithm at 3-month intervals for 24 months. Blood samples were also collected at the same time intervals. The main outcome measures were to assess if the reproductive health management was consistent with patient goals and to track any follicle-stimulating hormone (FSH) and thyroid-stimulating hormone (TSH) level changes throughout treatment and post-treatment period.

Purpose: The purpose of this study was to assess whether incorporation of an original reproductive health assessment and algorithm into breast cancer care helps providers appropriately manage patient reproductive health goals and to follow laboratory markers for fertility and correlate these with menstruation.

Results: Two patients were pregnant at study initiation. They received obstetric consultations, opted to continue pregnancies, and postpone treatment; both delivered at term without complications. One woman desired future childbearing and received fertility preservation counseling. All women received family planning consultations and received/continued effective contraceptive methods. Seventy-three percent used long-term contraception, 18 % remained abstinent, and 9 % used condoms. During chemotherapy, FSH rose to menopausal levels in 82 % of patients and TSH rose significantly in 9 %. While 82 % of women experienced amenorrhea, 44 % of these women resumed menstruation after chemotherapy.

Original languageEnglish (US)
Pages (from-to)411-418
Number of pages8
JournalSupportive Care in Cancer
Volume23
Issue number2
DOIs
StatePublished - Jan 1 2015

Fingerprint

Reproductive Health
Breast Neoplasms
Drug Therapy
Menstruation
Follicle Stimulating Hormone
Thyrotropin
Contraception
Referral and Consultation
Fertility Preservation
Public Hospitals
Urban Hospitals
Amenorrhea
Condoms
Family Planning Services
Obstetrics
Observational Studies
Fertility
Counseling
Therapeutics
Biomarkers

Keywords

  • Breast cancer
  • Contraception
  • Fertility
  • Reproductive endocrinology
  • Reproductive health

ASJC Scopus subject areas

  • Oncology

Cite this

Patel, A., Roston, A., Uy, A., Radeke, E., Roston, A., Keith, L., & Zaren, H. A. (2015). Reproductive health and endocrine disruption in women with breast cancer: a pilot study. Supportive Care in Cancer, 23(2), 411-418. https://doi.org/10.1007/s00520-014-2381-2

Reproductive health and endocrine disruption in women with breast cancer : a pilot study. / Patel, Ashlesha; Roston, Alicia; Uy, Almae; Radeke, Erika; Roston, Arden; Keith, Louis; Zaren, Howard A.

In: Supportive Care in Cancer, Vol. 23, No. 2, 01.01.2015, p. 411-418.

Research output: Contribution to journalArticle

Patel, A, Roston, A, Uy, A, Radeke, E, Roston, A, Keith, L & Zaren, HA 2015, 'Reproductive health and endocrine disruption in women with breast cancer: a pilot study', Supportive Care in Cancer, vol. 23, no. 2, pp. 411-418. https://doi.org/10.1007/s00520-014-2381-2
Patel, Ashlesha ; Roston, Alicia ; Uy, Almae ; Radeke, Erika ; Roston, Arden ; Keith, Louis ; Zaren, Howard A. / Reproductive health and endocrine disruption in women with breast cancer : a pilot study. In: Supportive Care in Cancer. 2015 ; Vol. 23, No. 2. pp. 411-418.
@article{0dd59896588e4b0793d24e490cb898fc,
title = "Reproductive health and endocrine disruption in women with breast cancer: a pilot study",
abstract = "Conclusions: The assessment and algorithm were useful in managing patients’ reproductive health needs. Chemotherapy-induced endocrine disruption impacted reproductive health.Methods: This prospective observational pilot study was set in an urban, public hospital. Newly diagnosed premenopausal breast cancer patients between 18 and 49 years old were recruited for this study prior to chemotherapy initiation. As the intervention, these patients received a reproductive health assessment and care per the study algorithm at 3-month intervals for 24 months. Blood samples were also collected at the same time intervals. The main outcome measures were to assess if the reproductive health management was consistent with patient goals and to track any follicle-stimulating hormone (FSH) and thyroid-stimulating hormone (TSH) level changes throughout treatment and post-treatment period.Purpose: The purpose of this study was to assess whether incorporation of an original reproductive health assessment and algorithm into breast cancer care helps providers appropriately manage patient reproductive health goals and to follow laboratory markers for fertility and correlate these with menstruation.Results: Two patients were pregnant at study initiation. They received obstetric consultations, opted to continue pregnancies, and postpone treatment; both delivered at term without complications. One woman desired future childbearing and received fertility preservation counseling. All women received family planning consultations and received/continued effective contraceptive methods. Seventy-three percent used long-term contraception, 18 {\%} remained abstinent, and 9 {\%} used condoms. During chemotherapy, FSH rose to menopausal levels in 82 {\%} of patients and TSH rose significantly in 9 {\%}. While 82 {\%} of women experienced amenorrhea, 44 {\%} of these women resumed menstruation after chemotherapy.",
keywords = "Breast cancer, Contraception, Fertility, Reproductive endocrinology, Reproductive health",
author = "Ashlesha Patel and Alicia Roston and Almae Uy and Erika Radeke and Arden Roston and Louis Keith and Zaren, {Howard A.}",
year = "2015",
month = "1",
day = "1",
doi = "10.1007/s00520-014-2381-2",
language = "English (US)",
volume = "23",
pages = "411--418",
journal = "Supportive Care in Cancer",
issn = "0941-4355",
publisher = "Springer Verlag",
number = "2",

}

TY - JOUR

T1 - Reproductive health and endocrine disruption in women with breast cancer

T2 - a pilot study

AU - Patel, Ashlesha

AU - Roston, Alicia

AU - Uy, Almae

AU - Radeke, Erika

AU - Roston, Arden

AU - Keith, Louis

AU - Zaren, Howard A.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Conclusions: The assessment and algorithm were useful in managing patients’ reproductive health needs. Chemotherapy-induced endocrine disruption impacted reproductive health.Methods: This prospective observational pilot study was set in an urban, public hospital. Newly diagnosed premenopausal breast cancer patients between 18 and 49 years old were recruited for this study prior to chemotherapy initiation. As the intervention, these patients received a reproductive health assessment and care per the study algorithm at 3-month intervals for 24 months. Blood samples were also collected at the same time intervals. The main outcome measures were to assess if the reproductive health management was consistent with patient goals and to track any follicle-stimulating hormone (FSH) and thyroid-stimulating hormone (TSH) level changes throughout treatment and post-treatment period.Purpose: The purpose of this study was to assess whether incorporation of an original reproductive health assessment and algorithm into breast cancer care helps providers appropriately manage patient reproductive health goals and to follow laboratory markers for fertility and correlate these with menstruation.Results: Two patients were pregnant at study initiation. They received obstetric consultations, opted to continue pregnancies, and postpone treatment; both delivered at term without complications. One woman desired future childbearing and received fertility preservation counseling. All women received family planning consultations and received/continued effective contraceptive methods. Seventy-three percent used long-term contraception, 18 % remained abstinent, and 9 % used condoms. During chemotherapy, FSH rose to menopausal levels in 82 % of patients and TSH rose significantly in 9 %. While 82 % of women experienced amenorrhea, 44 % of these women resumed menstruation after chemotherapy.

AB - Conclusions: The assessment and algorithm were useful in managing patients’ reproductive health needs. Chemotherapy-induced endocrine disruption impacted reproductive health.Methods: This prospective observational pilot study was set in an urban, public hospital. Newly diagnosed premenopausal breast cancer patients between 18 and 49 years old were recruited for this study prior to chemotherapy initiation. As the intervention, these patients received a reproductive health assessment and care per the study algorithm at 3-month intervals for 24 months. Blood samples were also collected at the same time intervals. The main outcome measures were to assess if the reproductive health management was consistent with patient goals and to track any follicle-stimulating hormone (FSH) and thyroid-stimulating hormone (TSH) level changes throughout treatment and post-treatment period.Purpose: The purpose of this study was to assess whether incorporation of an original reproductive health assessment and algorithm into breast cancer care helps providers appropriately manage patient reproductive health goals and to follow laboratory markers for fertility and correlate these with menstruation.Results: Two patients were pregnant at study initiation. They received obstetric consultations, opted to continue pregnancies, and postpone treatment; both delivered at term without complications. One woman desired future childbearing and received fertility preservation counseling. All women received family planning consultations and received/continued effective contraceptive methods. Seventy-three percent used long-term contraception, 18 % remained abstinent, and 9 % used condoms. During chemotherapy, FSH rose to menopausal levels in 82 % of patients and TSH rose significantly in 9 %. While 82 % of women experienced amenorrhea, 44 % of these women resumed menstruation after chemotherapy.

KW - Breast cancer

KW - Contraception

KW - Fertility

KW - Reproductive endocrinology

KW - Reproductive health

UR - http://www.scopus.com/inward/record.url?scp=84939878810&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84939878810&partnerID=8YFLogxK

U2 - 10.1007/s00520-014-2381-2

DO - 10.1007/s00520-014-2381-2

M3 - Article

C2 - 25120011

AN - SCOPUS:84939878810

VL - 23

SP - 411

EP - 418

JO - Supportive Care in Cancer

JF - Supportive Care in Cancer

SN - 0941-4355

IS - 2

ER -